Minerva Neurosciences Stock Price, News & Analysis (NASDAQ:NERV)

$5.55 +0.35 (+6.73 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$5.55
Today's Range$5.15 - $5.60
52-Week Range$4.80 - $11.15
Volume121,768 shs
Average Volume195,292 shs
Market Capitalization$201.24 million
P/E Ratio-4.96
Dividend YieldN/A
Beta1.49

About Minerva Neurosciences (NASDAQ:NERV)

Minerva Neurosciences logoMinerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company's product portfolio and indications include MIN-101 for the treatment of schizophrenia; MIN-202, for the treatment of insomnia disorder and major depressive disorder (MDD); MIN-117, for the treatment of MDD, and MIN-301 for the treatment of Parkinson's disease. MIN-101 is a compound that blocks serotonin receptors and sigma receptors, two receptors in the brain that are involved in the regulation of mood, cognition, sleep and anxiety. MIN-117 is meant to block a specific subtype of serotonin receptor called 5-hydroxytryptamine type 1A (5-HT1A). MIN-202 is a selective orexin 2 receptor antagonist. MIN-301 is a soluble recombinant form of the Neuregulin-1b1 (NRG-1b1) protein, for the treatment of Parkinson's disease.

Receive NERV News and Ratings via Email

Sign-up to receive the latest news and ratings for NERV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NERV
CUSIPN/A
Phone617-600-7373

Debt

Debt-to-Equity RatioN/A
Current Ratio15.38%
Quick Ratio15.38%

Price-To-Earnings

Trailing P/E Ratio-4.95531289899197
Forward P/E Ratio-4.34
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$3.04 per share
Price / Book1.83

Profitability

Trailing EPS($1.12)
Net Income$-31,040,000.00
Net MarginsN/A
Return on Equity-37.31%
Return on Assets-27.90%

Miscellaneous

Employees11
Outstanding Shares38,700,000

Minerva Neurosciences (NASDAQ:NERV) Frequently Asked Questions

What is Minerva Neurosciences' stock symbol?

Minerva Neurosciences trades on the NASDAQ under the ticker symbol "NERV."

How were Minerva Neurosciences' earnings last quarter?

Minerva Neurosciences, Inc (NASDAQ:NERV) issued its quarterly earnings results on Monday, November, 6th. The biopharmaceutical company reported ($0.28) EPS for the quarter, missing the consensus estimate of $0.00 by $0.28. During the same period in the prior year, the business posted ($0.24) EPS. View Minerva Neurosciences' Earnings History.

Where is Minerva Neurosciences' stock going? Where will Minerva Neurosciences' stock price be in 2018?

3 analysts have issued 12 month target prices for Minerva Neurosciences' shares. Their predictions range from $11.00 to $20.00. On average, they anticipate Minerva Neurosciences' stock price to reach $16.00 in the next year. View Analyst Ratings for Minerva Neurosciences.

What are Wall Street analysts saying about Minerva Neurosciences stock?

Here are some recent quotes from research analysts about Minerva Neurosciences stock:

  • 1. According to Zacks Investment Research, "Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. The Company's pipeline will initially target the treatment of schizophrenia, major depressive disorder (MDD), insomnia, and Parkinson's disease. Its product candidates include MIN-101, MIN-117, MIN-202 and MIN-301. Minerva Neurosciences, Inc. is based in Cambridge, MA, United States. " (10/5/2017)
  • 2. Jefferies Group LLC analysts commented, "We believe NERV's two candidates MIN-101 and -202 offer upside to shares. MIN-101, designed to treat negative symptoms in schizophrenia, an unmet need, has demonstrated stat sig benefits in PIIb. MIN-202, partnered with JNJ, may offer an effective tx to insomnia with fewer side effects, and has demonstrated positive data in PIIa with stat sig improvements in key sleep parameters. We assume with Buy and $17 PT." (3/6/2017)

Are investors shorting Minerva Neurosciences?

Minerva Neurosciences saw a decline in short interest in the month of January. As of January 31st, there was short interest totalling 1,179,041 shares, a decline of 35.4% from the January 12th total of 1,825,699 shares. Based on an average trading volume of 273,059 shares, the days-to-cover ratio is currently 4.3 days. Currently, 3.6% of the shares of the stock are sold short.

Who are some of Minerva Neurosciences' key competitors?

Who are Minerva Neurosciences' key executives?

Minerva Neurosciences' management team includes the folowing people:

  • Remy Luthringer Ph.D., Executive Chairman of the Board, Chief Executive Officer (Age 54)
  • Richard Russell, President (Age 53)
  • Geoffrey Race, Executive Vice President and Chief Financial Officer (Age 54)
  • Joseph Reilly, Chief Operating Officer, Vice President (Age 40)
  • Frederick Ahlholm CPA, Chief Accounting Officer, Vice President (Age 49)
  • Mark Levine, Vice President, General Counsel, Secretary (Age 43)
  • William F. Doyle, Lead Independent Director (Age 54)
  • Hans Peter Hasler, Director (Age 61)
  • David J Kupfer M.D., Independent Director (Age 75)
  • Fouzia Laghrissi-Thode M.D., Independent Director

Who owns Minerva Neurosciences stock?

Minerva Neurosciences' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Highland Capital Management LP (5.58%), BlackRock Inc. (5.22%), Franklin Resources Inc. (3.19%), Ascend Capital LLC (2.12%), Sphera Funds Management LTD. (2.00%) and Millennium Management LLC (0.51%). Company insiders that own Minerva Neurosciences stock include David Kupfer, Frederick W Ahlholm, Geoff Race, Joseph H Reilly, Marc D Beer, Mark S Levine, Remy Luthringer and Venture Associates L Index III. View Institutional Ownership Trends for Minerva Neurosciences.

Who sold Minerva Neurosciences stock? Who is selling Minerva Neurosciences stock?

Minerva Neurosciences' stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, BlackRock Inc., Millennium Management LLC, Bank of New York Mellon Corp and Schwab Charles Investment Management Inc.. Company insiders that have sold Minerva Neurosciences company stock in the last year include Frederick W Ahlholm, Geoff Race, Joseph H Reilly and Remy Luthringer. View Insider Buying and Selling for Minerva Neurosciences.

Who bought Minerva Neurosciences stock? Who is buying Minerva Neurosciences stock?

Minerva Neurosciences' stock was purchased by a variety of institutional investors in the last quarter, including Highland Capital Management LP, Sphera Funds Management LTD., Franklin Resources Inc., Ascend Capital LLC and Goldman Sachs Group Inc.. Company insiders that have bought Minerva Neurosciences stock in the last two years include David Kupfer and Marc D Beer. View Insider Buying and Selling for Minerva Neurosciences.

How do I buy Minerva Neurosciences stock?

Shares of Minerva Neurosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Minerva Neurosciences' stock price today?

One share of Minerva Neurosciences stock can currently be purchased for approximately $5.55.

How big of a company is Minerva Neurosciences?

Minerva Neurosciences has a market capitalization of $201.24 million. The biopharmaceutical company earns $-31,040,000.00 in net income (profit) each year or ($1.12) on an earnings per share basis. Minerva Neurosciences employs 11 workers across the globe.

How can I contact Minerva Neurosciences?

Minerva Neurosciences' mailing address is 1601 TRAPELO ROAD SUITE 284, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 617-600-7373 or via email at [email protected]


MarketBeat Community Rating for Minerva Neurosciences (NERV)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  132 (Vote Outperform)
Underperform Votes:  122 (Vote Underperform)
Total Votes:  254
MarketBeat's community ratings are surveys of what our community members think about Minerva Neurosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Minerva Neurosciences (NASDAQ:NERV) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $16.00$16.00$16.00$18.50
Price Target Upside: 164.46% upside164.46% upside164.46% upside85.00% upside

Minerva Neurosciences (NASDAQ:NERV) Consensus Price Target History

Price Target History for Minerva Neurosciences (NASDAQ:NERV)

Minerva Neurosciences (NASDAQ:NERV) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/1/2017CitigroupInitiated CoverageBuy$11.00HighView Rating Details
6/1/2017JMP SecuritiesReiterated RatingOutperform$17.00 -> $20.00LowView Rating Details
3/6/2017Jefferies GroupInitiated CoverageBuy -> Buy$17.00N/AView Rating Details
(Data available from 2/24/2016 forward)

Earnings

Minerva Neurosciences (NASDAQ:NERV) Earnings History and Estimates Chart

Earnings by Quarter for Minerva Neurosciences (NASDAQ:NERV)

Minerva Neurosciences (NASDAQ NERV) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017Q3 2017$0.00($0.28)ViewN/AView Earnings Details
8/3/2017Q2 2017($0.34)($0.27)ViewListenView Earnings Details
5/4/2017Q1 2017($0.30)($0.30)ViewListenView Earnings Details
3/13/2017Q4 2016($0.25)($0.27)ViewN/AView Earnings Details
11/3/2016Q316($0.21)($0.24)ViewListenView Earnings Details
8/4/2016Q116($0.30)($0.18)ViewListenView Earnings Details
5/3/2016Q1($0.33)($0.29)ViewListenView Earnings Details
3/14/2016Q4($0.31)($0.34)ViewListenView Earnings Details
11/5/2015Q315($0.43)($0.24)ViewListenView Earnings Details
8/5/2015Q215($0.53)($0.27)ViewN/AView Earnings Details
5/7/2015Q1 2015($0.64)($0.31)ViewN/AView Earnings Details
3/26/2015Q414($0.53)($0.40)ViewN/AView Earnings Details
11/6/2014Q3 2014($2.30)($1.53)ViewN/AView Earnings Details
8/7/2014Q2($0.41)($2.33)ViewListenView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Minerva Neurosciences (NASDAQ:NERV) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.28 EPS
Next Year EPS Consensus Estimate: $-1.5 EPS

Dividends

Dividend History for Minerva Neurosciences (NASDAQ:NERV)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Minerva Neurosciences (NASDAQ NERV) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 21.60%
Institutional Ownership Percentage: 71.50%
Insider Trades by Quarter for Minerva Neurosciences (NASDAQ:NERV)
Insider Trades by Quarter for Minerva Neurosciences (NASDAQ:NERV)

Minerva Neurosciences (NASDAQ NERV) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/14/2017Frederick W AhlholmSVPSell1,661$5.80$9,633.8010,000View SEC Filing  
12/14/2017Geoff RaceCFOSell5,829$5.79$33,749.91197,698View SEC Filing  
12/14/2017Joseph H ReillyCOOSell2,906$5.80$16,854.8017,083View SEC Filing  
12/14/2017Remy LuthringerCEOSell2,194$5.85$12,834.9018,750View SEC Filing  
3/20/2017Marc D BeerDirectorBuy50,000$8.12$406,000.0025,000View SEC Filing  
2/6/2017Geoff RaceCFOSell21,450$11.02$236,379.00186,890View SEC Filing  
2/6/2017Remy LuthringerCEOSell34,281$11.02$377,776.6232,096View SEC Filing  
1/11/2017Joseph H ReillyCOOSell1,600$12.03$19,248.009,933View SEC Filing  
1/4/2017Mark S LevineSVPSell17,500$12.00$210,000.0017,250View SEC Filing  
12/27/2016Frederick W AhlholmSVPSell17,000$12.51$212,670.0022,000View SEC Filing  
8/10/2016Venture Associates L Index IIIMajor ShareholderSell1,000,000$10.00$10,000,000.00View SEC Filing  
6/21/2016David KupferDirectorBuy55,635$10.84$603,083.40209,188View SEC Filing  
3/17/2016David KupferDirectorBuy181,488$5.51$999,998.88181,488View SEC Filing  
3/18/2015Care Capital Iii LlcMajor ShareholderSell1,206,700$5.75$6,938,525.00View SEC Filing  
3/18/2015Rubertis Francesco DeDirectorBuy202,634$4.81$974,669.54View SEC Filing  
3/13/2015& Johnson JohnsonMajor ShareholderBuy607,903$4.81$2,924,013.43View SEC Filing  
1/26/2015Care Capital Iii LlcMajor ShareholderSell482,112$5.11$2,463,592.32View SEC Filing  
1/8/2015Care Capital Iii LlcMajor ShareholderSell531,808$7.38$3,924,743.04View SEC Filing  
7/7/2014Care Capital Iii LlcMajor ShareholderBuy737,500$6.00$4,425,000.00View SEC Filing  
7/7/2014Michele OllierDirectorBuy1,620,833$6.00$9,724,998.00View SEC Filing  
7/1/2014Coelho Rogerio VivaldiCEOBuy41,667$6.00$250,002.00View SEC Filing  
7/1/2014Frederick W AhlholmCAOBuy10,000$6.00$60,000.00View SEC Filing  
7/1/2014Geoff RaceCFOBuy33,333$6.00$199,998.00View SEC Filing  
7/1/2014Heek G Jan VanDirectorBuy3,333$6.00$19,998.00View SEC Filing  
7/1/2014Joseph H ReillyInsiderBuy8,333$6.00$49,998.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Minerva Neurosciences (NASDAQ NERV) News Headlines

Source:
DateHeadline
Minerva Neurosciences, Inc (NERV) Given Average Recommendation of "Hold" by BrokeragesMinerva Neurosciences, Inc (NERV) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - February 23 at 1:44 AM
Zacks: Analysts Anticipate Minerva Neurosciences, Inc (NERV) to Announce -$0.43 Earnings Per ShareZacks: Analysts Anticipate Minerva Neurosciences, Inc (NERV) to Announce -$0.43 Earnings Per Share
www.americanbankingnews.com - February 22 at 5:08 AM
Minerva Neurosciences, Inc (NERV) Short Interest UpdateMinerva Neurosciences, Inc (NERV) Short Interest Update
www.americanbankingnews.com - February 12 at 4:08 AM
TBPH Inks $1Bln Deal, SGMO Hits Yearly High, ANAB Is Back AgainTBPH Inks $1Bln Deal, SGMO Hits Yearly High, ANAB Is Back Again
www.nasdaq.com - February 8 at 8:11 AM
BRIEF-Minerva Neurosciences Names Remy Luthringer As Executive ChairmanBRIEF-Minerva Neurosciences Names Remy Luthringer As Executive Chairman
www.reuters.com - February 5 at 9:40 AM
Minerva Neurosciences, Inc.: Minerva Neurosciences Names Remy Luthringer as Executive Chairman and William Doyle as Lead Independent DirectorMinerva Neurosciences, Inc.: Minerva Neurosciences Names Remy Luthringer as Executive Chairman and William Doyle as Lead Independent Director
www.finanznachrichten.de - February 5 at 9:40 AM
Minerva Neurosciences (NERV) Downgraded to Strong Sell at ValuEngineMinerva Neurosciences (NERV) Downgraded to Strong Sell at ValuEngine
www.americanbankingnews.com - February 4 at 8:40 PM
Head-To-Head Comparison: Minerva Neurosciences (NERV) & Its PeersHead-To-Head Comparison: Minerva Neurosciences (NERV) & Its Peers
www.americanbankingnews.com - February 2 at 5:12 PM
Minerva Neurosciences, Inc (NERV) Given Consensus Rating of "Hold" by BrokeragesMinerva Neurosciences, Inc (NERV) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - January 29 at 1:28 AM
Minerva Neurosciences (NERV) vs. Its Rivals Head-To-Head ReviewMinerva Neurosciences (NERV) vs. Its Rivals Head-To-Head Review
www.americanbankingnews.com - January 26 at 3:08 PM
-$0.43 Earnings Per Share Expected for Minerva Neurosciences, Inc (NERV) This Quarter-$0.43 Earnings Per Share Expected for Minerva Neurosciences, Inc (NERV) This Quarter
www.americanbankingnews.com - January 19 at 5:26 AM
Minerva Neurosciences (NERV) Upgraded at BidaskClubMinerva Neurosciences (NERV) Upgraded at BidaskClub
www.americanbankingnews.com - January 16 at 7:10 PM
Contrasting Minerva Neurosciences (NERV) and The CompetitionContrasting Minerva Neurosciences (NERV) and The Competition
www.americanbankingnews.com - January 7 at 9:10 AM
Minerva Neurosciences, Inc (NERV) Given Average Rating of "Hold" by BrokeragesMinerva Neurosciences, Inc (NERV) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - January 4 at 2:26 AM
Minerva Neurosciences (NERV) Downgraded by ValuEngineMinerva Neurosciences (NERV) Downgraded by ValuEngine
www.americanbankingnews.com - January 1 at 3:52 PM
Minerva Neurosciences (NERV) Announces Enrollment of First Patient in Phase 2b Trial Comparing Seltorexant vs ... - StreetInsider.comMinerva Neurosciences (NERV) Announces Enrollment of First Patient in Phase 2b Trial Comparing Seltorexant vs ... - StreetInsider.com
www.streetinsider.com - December 22 at 9:24 AM
BRIEF-Minerva Neurosciences Announces Enrollment Of First Patient In Phase 2B Trial Comparing Seltorexant Versus QuetiapineBRIEF-Minerva Neurosciences Announces Enrollment Of First Patient In Phase 2B Trial Comparing Seltorexant Versus Quetiapine
www.reuters.com - December 21 at 9:14 AM
Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial Comparing Seltorexant (MIN-202) Versus Quetiapine as Adjunctive Therapy to Antidepressants in Patients With Major Depressive DisorderMinerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial Comparing Seltorexant (MIN-202) Versus Quetiapine as Adjunctive Therapy to Antidepressants in Patients With Major Depressive Disorder
finance.yahoo.com - December 21 at 9:14 AM
Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial Comparing Seltorexant (MIN-202) Versus Quetiapine as Adjunctive Therapy to Antidepressants in Patients With...Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial Comparing Seltorexant (MIN-202) Versus Quetiapine as Adjunctive Therapy to Antidepressants in Patients With...
finance.yahoo.com - December 21 at 9:14 AM
Minerva Neurosciences (NERV) Announces Screening of First Patient in Phase 3 Trial Of MIN-101 to Treat Negative ... - StreetInsider.comMinerva Neurosciences (NERV) Announces Screening of First Patient in Phase 3 Trial Of MIN-101 to Treat Negative ... - StreetInsider.com
www.streetinsider.com - December 19 at 5:31 PM
BRIEF-Minerva Neurosciences Screens First Patient In Phase 3 Trial Of MIN-101 To Treat Negative Symptoms In SchizophreniaBRIEF-Minerva Neurosciences Screens First Patient In Phase 3 Trial Of MIN-101 To Treat Negative Symptoms In Schizophrenia
www.reuters.com - December 19 at 9:15 AM
Minerva Neurosciences Screens First Patient in Phase 3 Trial Of MIN-101 to Treat Negative Symptoms in SchizophreniaMinerva Neurosciences Screens First Patient in Phase 3 Trial Of MIN-101 to Treat Negative Symptoms in Schizophrenia
finance.yahoo.com - December 19 at 9:15 AM
Minerva Neurosciences, Inc (NERV) COO Joseph H. Reilly Sells 2,906 SharesMinerva Neurosciences, Inc (NERV) COO Joseph H. Reilly Sells 2,906 Shares
www.americanbankingnews.com - December 15 at 6:54 PM
Minerva Neurosciences, Inc (NERV) CFO Sells $33,749.91 in StockMinerva Neurosciences, Inc (NERV) CFO Sells $33,749.91 in Stock
www.americanbankingnews.com - December 15 at 6:54 PM
Minerva Neurosciences, Inc (NERV) CEO Sells $12,834.90 in StockMinerva Neurosciences, Inc (NERV) CEO Sells $12,834.90 in Stock
www.americanbankingnews.com - December 15 at 6:54 PM
BRIEF-Minerva Neurosciences names Richard Russell presidentBRIEF-Minerva Neurosciences names Richard Russell president
www.reuters.com - December 12 at 9:44 AM
Minerva Neurosciences Elects William Doyle and Hans Peter Hasler to Board of Directors - GlobeNewswire (press release)Minerva Neurosciences Elects William Doyle and Hans Peter Hasler to Board of Directors - GlobeNewswire (press release)
globenewswire.com - December 11 at 9:59 AM
Minerva Neurosciences, Inc (NERV) Receives Consensus Rating of "Hold" from BrokeragesMinerva Neurosciences, Inc (NERV) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - December 10 at 1:52 AM
Minerva Neurosciences (NERV) Reports Enrollment of First Patient in Phase 2b Trial of Seltorexant (MIN-202)Minerva Neurosciences (NERV) Reports Enrollment of First Patient in Phase 2b Trial of Seltorexant (MIN-202)
www.streetinsider.com - December 6 at 5:34 PM
Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial of Seltorexant (MIN-202) in Patients With Insomnia DisorderMinerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial of Seltorexant (MIN-202) in Patients With Insomnia Disorder
finance.yahoo.com - December 6 at 9:25 AM
FY2017 EPS Estimates for Minerva Neurosciences, Inc Cut by Analyst (NERV)FY2017 EPS Estimates for Minerva Neurosciences, Inc Cut by Analyst (NERV)
www.americanbankingnews.com - November 8 at 12:12 PM
Minerva Neurosciences, Inc (NERV) Releases Quarterly  Earnings ResultsMinerva Neurosciences, Inc (NERV) Releases Quarterly Earnings Results
www.americanbankingnews.com - November 7 at 11:53 AM
BRIEF-Minerva Neurosciences reports Q3 loss per share $0.28BRIEF-Minerva Neurosciences reports Q3 loss per share $0.28
www.reuters.com - November 7 at 7:31 AM
Minerva Neurosciences Inc to Host Earnings CallMinerva Neurosciences Inc to Host Earnings Call
finance.yahoo.com - November 7 at 7:31 AM
Minerva Neurosciences Reports Third Quarter 2017 Financial Results and Business UpdatesMinerva Neurosciences Reports Third Quarter 2017 Financial Results and Business Updates
finance.yahoo.com - November 7 at 7:31 AM
Minerva Neurosciences reports 3Q lossMinerva Neurosciences reports 3Q loss
finance.yahoo.com - November 7 at 7:31 AM
Edited Transcript of NERV earnings conference call or presentation 6-Nov-17 1:30pm GMTEdited Transcript of NERV earnings conference call or presentation 6-Nov-17 1:30pm GMT
finance.yahoo.com - November 7 at 7:31 AM
Minerva Neurosciences Names Dr. Justine Lalonde as Senior Vice President, Product Strategy - GlobeNewswire (press release)Minerva Neurosciences Names Dr. Justine Lalonde as Senior Vice President, Product Strategy - GlobeNewswire (press release)
globenewswire.com - November 2 at 6:47 AM
Minerva Neurosciences Names Dr. Justine Lalonde as Senior Vice President, Product StrategyMinerva Neurosciences Names Dr. Justine Lalonde as Senior Vice President, Product Strategy
feeds.benzinga.com - October 31 at 8:50 AM
Minerva Neurosciences to Report Third Quarter 2017 Financial Results and Business Updates on November 6, 2017Minerva Neurosciences to Report Third Quarter 2017 Financial Results and Business Updates on November 6, 2017
finance.yahoo.com - October 31 at 6:51 AM
Minerva Neurosciences, Inc (NERV) Set to Announce Quarterly Earnings on WednesdayMinerva Neurosciences, Inc (NERV) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - October 25 at 5:24 AM
Minerva Neurosciences, Inc (NERV) Given Average Recommendation of "Hold" by AnalystsMinerva Neurosciences, Inc (NERV) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - October 21 at 2:42 AM
Minerva Neurosciences, Inc (NERV) Lowered to "Hold" at Zacks Investment ResearchMinerva Neurosciences, Inc (NERV) Lowered to "Hold" at Zacks Investment Research
www.americanbankingnews.com - October 8 at 1:06 PM
Teligent, Inc. Announces FDA Approval Of Partnered ANDA For Desonide Lotion, 0.05%Teligent, Inc. Announces FDA Approval Of Partnered ANDA For Desonide Lotion, 0.05%
www.thestreet.com - October 2 at 5:51 PM
 Analysts Expect Minerva Neurosciences, Inc (NERV) to Announce -$0.27 Earnings Per Share Analysts Expect Minerva Neurosciences, Inc (NERV) to Announce -$0.27 Earnings Per Share
www.americanbankingnews.com - September 13 at 4:26 PM
Is Minerva Neurosciences Inc (NERV) Undervalued?Is Minerva Neurosciences Inc (NERV) Undervalued?
finance.yahoo.com - September 13 at 6:59 AM
Minerva Neurosciences Names Dr. Jay Saoud as Senior Vice President, Head of Research and DevelopmentMinerva Neurosciences Names Dr. Jay Saoud as Senior Vice President, Head of Research and Development
finance.yahoo.com - September 12 at 5:43 AM
Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial of Seltorexant (MIN-2Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial of Seltorexant (MIN-2
www.nasdaq.com - September 6 at 6:45 AM
BRIEF-Minerva Neurosciences announces enrollment of first patient in phase 2b trial of seltorexantBRIEF-Minerva Neurosciences announces enrollment of first patient in phase 2b trial of seltorexant
www.reuters.com - September 6 at 6:45 AM
Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial of Seltorexant (MIN-202) as Adjunctive Therapy in Patients With Major Depressive DisorderMinerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial of Seltorexant (MIN-202) as Adjunctive Therapy in Patients With Major Depressive Disorder
finance.yahoo.com - September 6 at 6:44 AM

SEC Filings

Minerva Neurosciences (NASDAQ:NERV) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Minerva Neurosciences (NASDAQ:NERV) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Minerva Neurosciences (NASDAQ NERV) Stock Chart for Saturday, February, 24, 2018

Loading chart…

This page was last updated on 2/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.